【康希诺生物(06185.HK):曼海欣®药品补充申请获得受理】智通财经APP讯,康希诺生物(06185.HK)发布公告,本公司已获得中国国家药品监督管理局(国家药监局)出具的《受理通知书》,根据该通知书,国家药监局已受理将本公司的ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)(
MCV4,商品名称:曼海欣®)的适用人群年龄范围由3月龄到6周岁( 83月龄)儿童扩大至3月龄到17周岁人群的补充申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.